Leadership Overview
Abdi İbrahim İlaç has 5 executives leading key functions including strategy, financial oversight, administrative support, human capital management, and biotechnology innovation.
Committed to advancing global health standards, Abdi İbrahim İlaç delivers essential pharmaceutical solutions while maintaining a legacy of excellence in the healthcare sector through continuous research and development.
Committed to advancing global health standards, Abdi İbrahim İlaç delivers essential pharmaceutical solutions while maintaining a legacy of excellence in the healthcare sector through continuous research and development.
Leadership Roles at Abdi İbrahim İlaç
Süha Taşpolatoğlu - Chief Executive Officer
Süha Taşpolatoğlu, the Chief Executive Officer at Abdi İbrahim İlaç, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the entire pharmaceutical portfolio, the Chief Executive Officer ensures alignment between research initiatives and market demands across international territories. This leadership role involves managing complex stakeholder relationships and driving operational excellence to maintain the company's competitive edge in the healthcare sector. By fostering a culture of innovation, Süha Taşpolatoğlu directly impacts the growth trajectory and market influence of the firm. The Chief Executive Officer coordinates with the board to secure financial stability while expanding the reach of life-saving medical products. Through rigorous oversight of manufacturing standards and clinical development, the Chief Executive Officer guarantees that the company meets the highest quality benchmarks. Ultimately, Taşpolatoğlu secures the future of the organization by navigating the evolving landscape of global pharmaceutical regulations and patient care requirements.
Mazhar Çavdar - Chief Financial Officer, Country
Mazhar Çavdar, the Chief Financial Officer, Country at Abdi İbrahim İlaç, manages the fiscal health and economic planning for regional operations. Overseeing capital allocation and budgetary discipline, the Chief Financial Officer, Country ensures that financial resources support the strategic goals of the pharmaceutical business. This leadership role involves analyzing market trends to optimize revenue streams and mitigate financial risks within the healthcare sector. By implementing robust accounting frameworks, Mazhar Çavdar directly impacts the operational efficiency and profitability of the firm. The Chief Financial Officer, Country collaborates with executive leadership to evaluate investment opportunities in new drug development and infrastructure expansion. Through precise financial forecasting and reporting, the Chief Financial Officer, Country provides the transparency necessary for informed decision-making at the highest levels. Ultimately, Çavdar maintains the fiscal integrity of the company while supporting sustainable growth across diverse regional markets and complex regulatory environments.
Gülçin Oğuz - Chief Financial Officer Asistanı
Gülçin Oğuz, the Chief Financial Officer Asistanı at Abdi İbrahim İlaç, facilitates the administrative and operational workflows within the finance department. Overseeing the coordination of financial documentation and executive communications, the Chief Financial Officer Asistanı ensures that fiscal processes remain organized and efficient. This leadership role involves supporting the financial planning team in tracking expenditures and managing internal reporting cycles for the pharmaceutical business. By streamlining communication between finance and other corporate divisions, Gülçin Oğuz directly impacts the speed and accuracy of financial decision-making. The Chief Financial Officer Asistanı assists in the preparation of critical data for board reviews and strategic planning sessions. Through meticulous attention to detail and process management, the Chief Financial Officer Asistanı maintains the operational flow of the finance office. Ultimately, Oğuz supports the broader financial objectives of the company by ensuring that the executive team possesses the necessary information to drive growth and maintain fiscal health.
M. Oğuzcan - President, Human Resources, Communications & Sustainability
M. Oğuzcan, the President, Human Resources, Communications & Sustainability at Abdi İbrahim İlaç, architects the organizational culture and corporate social responsibility initiatives. Overseeing talent acquisition, employee development, and internal communications, the President, Human Resources, Communications & Sustainability ensures that the workforce remains aligned with the mission of providing pharmaceutical services. This leadership role involves integrating sustainability practices into the core business model to enhance the company's reputation in the healthcare sector. By fostering an inclusive and high-performing environment, M. Oğuzcan directly impacts employee retention and corporate brand equity. The President, Human Resources, Communications & Sustainability collaborates with other executives to promote ethical standards and environmental stewardship across all manufacturing operations. Through strategic engagement programs, the President, Human Resources, Communications & Sustainability strengthens the connection between the company and the communities served. Ultimately, Oğuzcan drives the long-term social impact and human capital strategy necessary for sustained organizational success.
Aydin Ozuer - President & Biotechnology, Abdibio Executive Board Member
Aydin Ozuer, the President & Biotechnology, Abdibio Executive Board Member at Abdi İbrahim İlaç, leads the advanced research and development of biological pharmaceutical products. Overseeing the biotechnology division, the President & Biotechnology, Abdibio Executive Board Member ensures that the company remains at the forefront of medical innovation. This leadership role involves managing complex clinical trials and scaling production capabilities for specialized therapies within the healthcare sector. By directing the scientific strategy for the Abdibio unit, Aydin Ozuer directly impacts the development of next-generation treatments. The President & Biotechnology, Abdibio Executive Board Member collaborates with the board to prioritize investments in cutting-edge technology and laboratory infrastructure. Through rigorous oversight of scientific protocols and regulatory compliance, the President & Biotechnology, Abdibio Executive Board Member guarantees the safety and efficacy of new product pipelines. Ultimately, Ozuer secures the company's position as a leader in biotechnology by translating scientific breakthroughs into tangible patient health outcomes.
Explore Leadership Teams in Manufacturing
Boehringer Ingelheim is a privately held, research-driven pharmaceutical company headquartered in Ingelheim am Rhein, Germany, founded in 1885. The company researches, develops, and manufactures prescription medicines and healthcare products across three core business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Its primary therapeutic focus areas include respiratory diseases, oncology, immunology, cardiometabolic conditions, and central nervous system disorders. Boehringer Ingelheim also develops and manufactures veterinary products for companion animals, livestock, and poultry. Operating in over 100 countries with more than 53,000 employees globally, the company maintains a broad network of research, manufacturing, and commercial sites across Europe, North America, and Asia. It is one of the largest privately owned pharmaceutical companies in the world.
Company Leadership DP
SG
AG
Abbott is a global healthcare company that develops and delivers a broad range of medical technologies, diagnostics, nutrition products, and branded generic medicines. The company is focused on improving health outcomes and helping people live healthier lives across all stages of life. Its mission centers on creating innovative solutions that address important medical needs, including chronic disease management, cardiovascular care, diabetes care, and pain management.
Company Leadership FS
SG
PQ
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Leadership CD
NB
ES
SS
Founded in 2005, Headquartered in Tokyo, Daiichi Sankyo is a global pharmaceutical company that develops and provides innovative new and generic medicines, as well as advanced drug discovery and delivery methods, serving patients in over 30 countries.
Company Leadership KM
CS
ST
Frequently Asked Questions Regarding Abdi İbrahim İlaç Top Executives and Leadership Team
